{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:17:49Z","timestamp":1648675069477},"reference-count":60,"publisher":"University of Tokushima Faculty of Medicine","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Invest."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2152\/jmi.62.251","type":"journal-article","created":{"date-parts":[[2015,9,17]],"date-time":"2015-09-17T22:07:46Z","timestamp":1442527666000},"page":"251-257","source":"Crossref","is-referenced-by-count":0,"title":["Unusual endoscopic findings of gastric neuroendocrine tumor"],"prefix":"10.2152","volume":"62","author":[{"given":"Kazuhiro","family":"Kishi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Kagawa Prefectural Shirotori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kagawa Prefectural Shirotori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Horikita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kagawa Prefectural Shirotori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kagawa Prefectural Shirotori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Ooshimo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kagawa Prefectural Shirotori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Oncology, Tokushima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Oncology, Tokushima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-che","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Oncology, Tokushima University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"925","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kl\u00f6ppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014: 13-27, 2004","DOI":"10.1196\/annals.1294.002"},{"key":"2","unstructured":"2. Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO classification or Tumors of the Digestive System, 4<sup>th<\/sup> Edition. IARC Press, Lyon, France, 2010"},{"key":"3","unstructured":"3. Matsusaka T, Watanabe H, Enjoji M: Oat-Cell Carcinoma of the Stomach. Fukuoka Acta Medica 67: 65-73, 1976"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK: Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 145: 276-280, 2010","DOI":"10.1001\/archsurg.2010.10"},{"key":"5","unstructured":"5. Matsui K, Kitagawa M, Miwa A, Kuroda Y, Tsuji M: Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases. Am J Gastroenterol 86: 1167-1175, 1991"},{"key":"6","unstructured":"6. Fukuda T, Ohnishi Y, Nishimaki T, Ohtani H, Tachikawa S: Early gastric cancer of the small cell type. Am J Gastroenterol 83: 1176-1179, 1988"},{"key":"7","unstructured":"7. Nobin A, Ahren B, Ahlman H: Endocrine tumors in the gastrointestinal tract. Nord Med 103: 12-14, 1988"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jass JR, Sobin LH, Watanabe H: The World Health Organization&apos;s histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer 66: 2162-2167, 1990","DOI":"10.1002\/1097-0142(19901115)66:10<2162::AID-CNCR2820661020>3.0.CO;2-N"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tanemura H, Ohshita H, Kanno A, Kusakabe M, Tomita E, Nishigaki Y, Sugiyama A, Yamada T: A patient with small-cell carcinoma of the stomach with long term survival after percutaneous microwave coagulating therapy (PMCT) for liver metastasis. Int J Clin Oncol 7: 128-132, 2002","DOI":"10.1007\/s101470200018"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, Taniguchi H, Shirao K: Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 14: 161-165, 2011","DOI":"10.1007\/s10120-011-0025-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Spampatti MP, Massironi S, Rossi RE, Conte D, Sciola V, Ciafardini C, Ferrero S, Lodi L, Peracchi M: Unusually aggressive type 1 gastric carcinoid: a case report with a review of the literature. Eur J Gastroenterol Hepatol 24: 589-593, 2012","DOI":"10.1097\/MEG.0b013e328350fae8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I: Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol 30: 945-953, 2006","DOI":"10.1097\/00000478-200608000-00003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rindi G, Ombretta L, Cornaggia M, Capella C, Solcia E: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104: 994-1006, 1993","DOI":"10.1016\/0016-5085(93)90266-F"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rindi G, D&apos;Adda T, Froio E, Fellegara G, Bordi C: Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 18: 145-149, 2007","DOI":"10.1007\/s12022-007-0020-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shin Y, Ha SY, Hyeon J, Lee B, Jang KT, Kim KM, Park YS, Park CK: Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: a Clinicopathological Analysis of 72 Cases in a Single Institute. Cancer Research and Treatment <i>in press<\/i>","DOI":"10.4143\/crt.2014.224"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kusaka T, Sano Y, Arao J, Ichikawa K, Yamamura-Idei Y, Shimizu S, Tsuchiya K, Ueda Y, Chiba T, Fujimori T: A huge polypoid early gastric neuroendocrine cell carcinoma. Dig Endosc 10: 236-239, 1998","DOI":"10.1111\/j.1443-1661.1998.tb00565.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nishikura K, Watanabe H, Iwafuchi M, Fujikura T, Kojima K, Ajioka Y: Carcinogenesis of gastric endocrine cell carcinoma: analysis of histopathology and p53 gene alteration. Gastric Cancer 6: 203-209, 2003","DOI":"10.1007\/s10120-003-0249-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kunke MH, Wu B, Ryan D, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS: A Phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51: 1033-1038, 2006","DOI":"10.1007\/s10620-006-8001-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T: Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 105: 1176-1181, 2014","DOI":"10.1111\/cas.12473"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study Ann Oncol 24: 152-160, 2013","DOI":"10.1093\/annonc\/mds276"},{"key":"21","unstructured":"21. Poiana C, Neamtu MC, Avramescu ET, Carsote M, Trifanescu R, Terzea D, Neamtu OM, Ferechide D, Miulescu RD: The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol 54: 717-720, 2013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kim SY, Woo IS, Yang JH, Han CW, Roh SY, Jung YH: A Case of Metastatic Gastric Neuroendocrine Tumor: Therapeutic Considerations. Case Rep Oncol 7: 266-272, 2014","DOI":"10.1159\/000362516"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bl\u00e4ker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656-4663, 2009","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pl\u00f6ckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour\/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 87: 20-30, 2008","DOI":"10.1159\/000109876"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kidd M, Gustafsson BJ: Management of Gastric Carcinoids (Neuroendocrine Neoplasms) Curr Gastroenterol Rep 14: 467-472, 2012","DOI":"10.1007\/s11894-012-0289-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. \u00d6berg K: Biotherapies for GEP-NETs. Best Practice &amp; Research Clinical Gastroenterology 26: 833-841, 2012","DOI":"10.1016\/j.bpg.2013.01.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Faiss S, Pape UF, B\u00f6hmig M, D\u00f6rffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B: International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689-96, 2003","DOI":"10.1200\/JCO.2003.12.142"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Cutsem EV, Hobday, TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Marianne E, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, \u00d6berg K for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 364: 514-523, 2011","DOI":"10.1056\/NEJMoa1009290"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Catherine Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, H\u00f6rsch D, Hammel P, Wiedenmann B, Cutsem EV, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 364: 501-513, 2011","DOI":"10.1056\/NEJMoa1003825"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10: 145-147, 2004","DOI":"10.1038\/nm988"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Fl\u00e9jou J, Degott C: Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32: 133-138, 1998","DOI":"10.1046\/j.1365-2559.1998.00321.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519-523, 1992","DOI":"10.1056\/NEJM199202203260804"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001 12: 1139-4113, 2001","DOI":"10.1023\/A:1011632713360"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 73: 1505-1508, 1994","DOI":"10.1002\/1097-0142(19940301)73:5<1505::AID-CNCR2820730530>3.0.CO;2-V"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006 24: 401-406, 2006","DOI":"10.1200\/JCO.2005.03.6046"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13: 2986-2991, 2007","DOI":"10.1158\/1078-0432.CCR-06-2053"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30: 2963-2968, 2012","DOI":"10.1200\/JCO.2011.40.3147"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117: 268-275, 2011","DOI":"10.1002\/cncr.25425"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22: 4762-4771, 2004","DOI":"10.1200\/JCO.2004.04.024"},{"key":"40","unstructured":"40. Moertel CG, Hanley JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2: 327-334, 1979"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2: 1255-1259, 1984","DOI":"10.1200\/JCO.1984.2.11.1255"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group: Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23: 4897-4904, 2005","DOI":"10.1200\/JCO.2005.03.616"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Fj\u00e4llskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92: 1101-1107, 2001","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS: A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51: 1033-1038, 2006","DOI":"10.1007\/s10620-006-8001-3"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Pavel ME, Hainsworth JD, Baudin E, Peeters M, H\u00f6rsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Lancet 378: 2005-2012, 2011","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, H\u00f6rsch D, Van Cutsem E, \u00d6berg K, Yao JC: Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology <i>in press<\/i>","DOI":"10.1159\/000381715"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F: Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer 120: 2457-2463, 2014","DOI":"10.1002\/cncr.28726"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C: Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol <i>in press<\/i>.","DOI":"10.1200\/JCO.2014.56.2082"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA: Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26: 1316-1323, 2008","DOI":"10.1200\/JCO.2007.13.6374"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M: Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)-a phase II non-randomised trial. Eur J Cancer 50: 3107-3115, 2014","DOI":"10.1016\/j.ejca.2014.10.001"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Ducreux M, Dahan L, Smith D, O&apos;Toole D, Lep\u00e8re C, Dromain C, Vilgrain V, Baudin E, Lombard-Bohas C, Scoazec JY, Seitz JF, Bitoun L, Kon\u00e9 S, Mitry E: Bevacizumab combined with 5-FU\/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)-a phase II non-randomised trial. Eur J Cancer 50: 3098-3106, 2014","DOI":"10.1016\/j.ejca.2014.10.002"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS: Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas 44: 190-197, 2015","DOI":"10.1097\/MPA.0000000000000255"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D&apos;Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer 14: 184, 2014","DOI":"10.1186\/1471-2407-14-184"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS: A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 68: 293-300, 2011","DOI":"10.1007\/s00280-010-1478-7"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, Garc\u00eda-Carbonero R, Manzano Mozo JL, Sevilla I, Dur\u00e1n I, Salazar R: Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer 49: 3780-3787, 2013","DOI":"10.1016\/j.ejca.2013.06.042"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Firdaus I, Shih KC, Zakari A, Lang EZ, McCleod M, Alguire KB, Peacock NW, Flora DB, Ruehman P, Earwood C, Bendell JC: Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET). J Clin Oncol 30(Suppl): Abstract 2127, 2012","DOI":"10.1200\/jco.2012.30.15_suppl.4127"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, Dimitriadis G, Kaltsas G: Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer 19: L1-4, 2012","DOI":"10.1530\/ERC-11-0287"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L: Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 9: 388, 2009","DOI":"10.1186\/1471-2407-9-388"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS: Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer 109: 1414-1419, 2013","DOI":"10.1038\/bjc.2013.470"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Varker KA, Campbell J, Shah MH: Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61: 661-668, 2008","DOI":"10.1007\/s00280-007-0521-9"}],"container-title":["The Journal of Medical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/62\/3.4\/62_251\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T12:16:45Z","timestamp":1599567405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/62\/3.4\/62_251\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":60,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2152\/jmi.62.251","relation":{},"ISSN":["1343-1420","1349-6867"],"issn-type":[{"value":"1343-1420","type":"print"},{"value":"1349-6867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}